Bart Fevery - Infectious Diseases

Author Information

Bart Fevery is affiliated with Janssen Infectious Diseases BVBA, located in Beerse, Belgium. His work predominantly focuses on infectious diseases, with a particular interest in virology and pharmacological treatments for viral infections.

Research Contributions

Bart Fevery has made significant contributions to the field of infectious diseases, particularly in the study and treatment of hepatitis C virus (HCV) infections. His research has explored the efficacy and safety of various antiviral drugs, such as simeprevir and sofosbuvir, both in combination and as standalone treatments. He has been involved in numerous clinical trials, assessing the pharmacokinetics and pharmacodynamics of these treatments in different patient populations, including those with varied genotypes of HCV. His recent work also delves into the development and evaluation of TLR-7 agonists, which are promising in the modulation of immune responses.

Aliases

Bart Fevery is also known by the aliases B. Fevery and B Fevery.

Publication and Citation Metrics

Metric	Value
Total Papers	43
Citation Count	2204
H-index	18

Publications:

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults

DOI: 10.1177/13596535211056581

Year: 2021

FRI-198-A Phase, double-blind, randomized, placebo-controlled, first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral JNJ-64794964, a toll-like receptor-7 agonist, in healthy adults

DOI: 10.1016/S0618-8278(19)30943-0

Year: 2019

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1

DOI: 10.1002/hep.30527

Year: 2019

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

DOI: 10.1186/s12985-018-0936-4

Year: 2018

In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir

DOI: 10.1016/S0168-8278(17)31470-8

Year: 2017

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study

DOI: 10.1186/s12879-017-2444-3

Year: 2017

Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study

DOI: 10.1111/jvh.12614

Year: 2017

Simeprevir in combination with sofosbuvir in treatment‐naïve and ‐experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open‐label, single‐arm study (PLUTO)

DOI: 10.1111/apt.13883

Year: 2017

Consistent Simeprevir Resistance Profile in Hepatitis C Virus Genotype 1-Infected Patients Failing Simeprevir Interferon-Free Compared with Interferon-Containing Regimens

DOI: 10.1016/S0168-8278(16)00627-9

Year: 2016

Simeprevir plus Sofosbuvir for Hepatitis C Virus Genotype 4 Infection: A Phase 3, Open-Label Study

DOI: 10.1016/S0168-8278(16)00193-8

Year: 2016

Are condoms effective against all STIs?

What Should You Discuss with Your Healthcare Provider?

What are the benefits of good hygiene practices?

What are the Objectives of the RBM Partnership?

How to Use Antibiotics Responsibly?

What Are Some of WHO’s Recent Initiatives in Infectious Disease Control?

How are Protein Targets Identified?

How Can Measles be Prevented?

What are Receptors?

What is the Global Impact of Dengue Hemorrhagic Fever?

Partnered Content Networks

Relevant Topics